Sharon Rosenzwieg-lipson PhD

Sharon Rosenzweig-Lipson, PhD, has served as our Vice President of Research and Development since 2011. She offers AgeneBio expertise in screening strategies, in vivo models, translation and early clinical development strategy. She has more than 25 years of experience developing compounds for psychiatric and neurologic indications in the pharmaceutical industry, including American Cyanamid, American Home Products, Wyeth and Pfizer. She earned her PhD in Behavioral Neuroscience from Harvard University